HER-2 POSITIVE BREAST CANCER

This adverse event was reported 140 times

These drugs are most commonly taken by patients reporting HER-2 POSITIVE BREAST CANCER:

# Drug Count
0 TRASTUZUMAB 68
1 PERTUZUMAB 20
2 CYCLOPHOSPHAMIDE 19
3 CYCLOPHOSPHAMIDE FOR INJECTION 19
4 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 19
5 DOCETAXEL 19
6 DOCETAXEL ANHYDROUS 19
7 CAPECITABINE 18
8 ADO-TRASTUZUMAB EMTANSINE 13
9 LAPATINIB 13
See all common drugs associated with HER-2 POSITIVE BREAST CANCER

HER-2 POSITIVE BREAST CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 HER2/neu Receptor Antagonist [EPC] 68 0.0009
1 Calcitonin [EPC] 1 0.0003
2 Aromatase Inhibitor [EPC] 19 0.0002
3 Microtubule Inhibitor [EPC] 27 0.0002
4 Somatostatin Analog [EPC] 1 0.0001
5 CD52-directed Cytolytic Antibody [EPC] 2 0.0001
6 Estrogen Receptor Antagonist [EPC] 4 0.0001
7 Nucleoside Metabolic Inhibitor [EPC] 23 0.0001
8 Alkylating Drug [EPC] 20 0.0001
9 Prostaglandin E1 Analog [EPC] 1 0.0001
See all drug classes enriched for association with HER-2 POSITIVE BREAST CANCER